Pfizer once again takes out the budget ax and lops off 150 R&D staffers and 5 preclinical biosimilar drugs

Pfizer is taking the ax to its preclinical R&D group for biosimilars in a move designed to end — at least for now — any new expansion of the pipeline for knockoffs.